Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 14/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331710 | 0.78 | — | — | |
| SCHEMBL30842078 | 0.78 | — | — | |
| SCHEMBL1376899 | 0.77 | NUDT1 (0.32) | — | |
| SCHEMBL10017439 | 0.77 | EDNRB (0.37) | FEN1ALOX5APMEN1KMT2ARXRA | |
| SCHEMBL21037437 | 0.76 | — | — | |
| SCHEMBL11076895 | 0.75 | SCN9A (0.47) | SCN9ANOS3NOS1NOS2FEN1 | |
| SCHEMBL8958798 | 0.75 | SCN9A (0.33) | SCN9ARXRAGRIN1GRIN2B | |
| SCHEMBL19073173 | 0.75 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL12603734 | 0.75 | — | — | |
| SCHEMBL14880201 | 0.73 | SCN9A (0.46) | SCN9ANOS3NOS1NOS2FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017077552-A1 | PROCESS FOR THE PREPARATION OF SOFOSBUVIR | MYLAN LABORATORIES LIMITED (IN) | 2017-05-11 | — | — | WO | disclosed |
| US-8193339-B2 | Synthesis of β-nucleosides | PHARMAESSENTIA CORP. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-20090124797-A1 | NOVEL SYNTHESIS OF BETA-NUCLEOSIDES | PHARMAESSENTIA CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124797-A1 | NOVEL SYNTHESIS OF BETA-NUCLEOSIDES | DUT, DCTD, UMPS | SCN9A 1273/4885NOS3 3183/4885NOS1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.